Archive for July 8th, 2011

Alkermes, Inc. (NASDAQ: ALKS) on Thursday announced that topline results from a Phase 2 clinical study of ALKS 33 in the treatment of binge eating disorder did not meet its efficacy endpoint and is likely to discontinue further studies in the binge eating indication. It also mentioned together with Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN), Eli […]

Latest Articles

Dear readers of BioPharmCatalyst, Thank you to all readers who have followed and supported BioPharmCatalyst over the past five years. Yes, that’s correct, BioPharmCatalyst celebrated it’s 5th anniversary earlier this week. BPC is run independently and a change in working circumstances has meant that updating the website has become quite time consuming to maintain over the past […]

Latest updates to the Company Pipeline Database for May 18 and 19, 2015. Refer to the FDA Calendar for upcoming catalysts: In addition, over 100 updates were made over the weekend as companies continued with their reporting season. You can find the updates from last week by clicking the “updated” column on the far right of the Company Pipeline Database. […]